EUR > Medicine & Health > Erasmus MC > View Article
http://hdl.handle.net/1765/23522

scopus: cited 6 times
web of science: cited 4 times

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors


Article
volume 29, issue 1 pp 137-143.
Related Files
asset icon
(00212.pdf, 0.1MB)

(publisher's version.url.txt, 43 bytes)

Summary: Purpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR; VEGFR-2) and fms-related tyrosine kinase 4 (FLT4; VEGFR-3). This study aims at the identification of relationships between single nucleotide polymorphisms (SNPs) in genes encoding for transporter proteins and pharmacokinetic parameters in order to clarify the significant interpatient variability in drug exposure. In addition, the potential relationship between target receptor polymorphisms and toxicity of telatinib is explored. Methods Blood samples from 33 patients enrolled in a phase I dose-escalation study of telatinib were analyzed. For correlation with dose normalized AUC(0-12), ATP-binding cassette (ABC) B1 (ABCB1), ABCC1, and ABCG2 were the genes selected. For correlation with telatinib toxicity, selected genes were the drug target genes KDR and FLT4. Results No association between dose normalized AUC(0-12) and drug transporter protein polymorphisms was observed. In addition, no association between toxicity and KDR or FLT4 genotype or haplotype was seen. Conclusions Our pharmacogenetic analysis could not reveal a correlation between relevant gene polymorphisms and clinical and pharmacokinetic observations of telatinib.



Keywords


Automatically Extracted Terms
  • toxicity
  • telatinib
  • patient
  • polymorphism
  • study
  • association
  • cancer
  • treatment
  • pharmacokinetic
  • grade
  • pharmacogenetic
  • side effects
  • phase
  • p-value
  • receptor
  • parameter
  • number
  • genotype
  • transporter
  • target


Bookmark with: